News for hackers. Stuff that matters.
Re:Steve Jobs To Take ‘Medical Leave Of Absence’, Stays On A... by laujen on Monday January 17, 2011 @09:08AM (#2112147)
Hope he is okay. If it is pancreatic cancer again, his odds are not good. My aunt had it, beat it, then it reoccurred four years later. She did not make it the second time. Only 2% survive. Good luck, Steve. Whether you like Apple or not, tech is much more interesting with Steve Jobs around.
Re:Steve Jobs To Take ‘Medical Leave Of Absence’, Stays On A... by acangiano on Monday January 17, 2011 @10:32AM (#2112390)
Truly sorry to hear about your loss. Actual pancreatic cancer is virtually incurable, and far too few resources are allocated to its research versus less deadly cancers.

For example, breast cancer affects around 207K people (yes, even men get it, albeit rarely) and ends up killing around 40K people a year. Pancreatic cancer affects 43K people, and ends up killing 37K every year. [1]

All cancer research is important, but we should really step up as a society when it comes to cancers that happens to be a dead sentence over the course of 5 years or so.

I personally donate to the Pancreatic Cancer Action Network, and you can do the same here: http://www.pancan.org/

[1] http://www.cancer.gov/cancertopics/types/commoncancers

Re:Steve Jobs To Take ‘Medical Leave Of Absence’, Stays On A... by fbailey on Monday January 17, 2011 @11:37AM (#2112586)
It's difficult to decide what should be funded, just because you throw money at a problem doesn't mean a solution will suddenly appear. For a look into the history of cancer research I recommend http://www.amazon.com/Emperor-All-Maladies-Biography-Cancer/...
Re:Steve Jobs To Take ‘Medical Leave Of Absence’, Stays On A... by natnat on Monday January 17, 2011 @02:08PM (#2113041)
Actually, Steve Jobs is quite lucky. His type of pancreatic cancer, called islet cell carcinoma, has a much better prognosis than most other types of pancreatic cancer. It is also quite rare, making up only 1.3% of pancreatic cancer cases.